Brief: Kancera Q4 R&D Expenses Amounted To SEK 17.1 Mln

Novakand Pharma AB

23/02/2024 07:37

Feb 23 (Reuters) - Kancera AB  KANC.ST :
    * Q4 R&D EXPENSES AMOUNTED TO SEK 17.1 MILLION (SEK 11.6
MILLION)

Source text for Eikon:  ID:nMFN4vFyJZ 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))